Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
2,523
Views
15
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML

Erik Delsing Malmberga Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden;
,
Sofie Johansson Alma Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden;
,
Malin Nicklassonb Department of Medicine, Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden;
,
Vladimir Lazarevicc Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden;
,
Sara Ståhlmand Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden;
,
Tore Samuelssone Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden;
,
Stig Lenhoffc Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden;
,
Julia Aspa Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; ;d Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden;
,
Mats Ehingerf Division of Oncology and Pathology, Lund University, Lund, Sweden
,
Lars Palmqvista Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; ;d Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden;
,
Mats Bruneb Department of Medicine, Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden;
&
Linda Fogelstranda Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; ;d Department of Clinical Chemistry, Sahlgrenska University Hospital, Gothenburg, Sweden; Correspondence[email protected]
 show all
Pages 409-417 | Received 12 Feb 2018, Accepted 27 May 2018, Published online: 02 Aug 2018

Related Research Data

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
Source: American Society of Hematology
Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration
Source: American Society of Hematology
Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse
Source: Ferrata Storti Foundation (Haematologica)
NPM1 vs. WT1 as MRD markers in AML
Source: Wiley
High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)
Source: American Society of Hematology
Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation
Source: Elsevier BV
Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
Source: American Society of Hematology
Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.
Source: American Society of Hematology
Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.
Source: MDPI AG
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations
Source: Elsevier BV
Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study
Source: American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Source: Springer Science and Business Media LLC
PEAR: a fast and accurate Illumina Paired-End reAd mergeR
Source: Oxford University Press (OUP)
MFC vs. RQ-PCR in MRD Detection in AML
Source: Wiley
Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation.
Source: Walter de Gruyter GmbH
Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
Source: Springer Science and Business Media LLC
NOTCH Activation in T-Cell Leukemia
Source: Wiley
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).
Source: American Society of Hematology
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.
Source: Informa UK Limited
Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients
Source: American Society of Hematology
Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia
Source: American Society of Hematology

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.